Press Releases

15/03/2023 OSE Immunotherapeutics to Present Preclinical and Clinical Research Updates from its Pipeline and Platforms in Immuno-Oncology at the 2023 American Association for Cancer Research (AACR)
01/03/2023 OSE Immunotherapeutics Receives New Approval for an Early Access Program for Tedopi® in Spain in Non-Small Cell Lung Cancer After Failure to Immunotherapies
22/02/2023 OSE Immunotherapeutics Updates on Anti-IL-7 Receptor Antagonist OSE-127/S95011, a Breakthrough Approach in Chronic Inflammatory Autoimmune Diseases and Hematology
15/02/2023 OSE Immunotherapeutics Provides Regulatory Update on Tedopi®, a Cancer Vaccine at a Late-Stage Clinical Development in Lung Cancer After Failure to Immunotherapies
03/01/2023 OSE Immunotherapeutics Announces Upcoming Investor Meetings in Q1 2023
22/12/2022 OSE Immunotherapeutics Announces First Patient Dosed with Anti-PD1 Monoclonal Antibody OSE-279 in a Phase 1/2 Clinical Trial in Advanced Solid Tumors or Lymphomas
16/12/2022 OSE Immunotherapeutics Receives a €10 Million Payment Corresponding to the Second Tranche of the Financing Granted by the European Investment Bank
12/12/2022 OSE Immunotherapeutics Announces Latest Preclinical Efficacy Data on its Anti-IL-7 Receptor Antagonist OSE-127 in Acute Lymphoblastic Leukemia at the 2022 American Society of Hematology (ASH) Annual Meeting
21/11/2022 OSE Immunotherapeutics Announces Publication of Peer-Reviewed Data on CLEC-1, its Novel Myeloid Immune Checkpoint in ‘Science Advances’
08/11/2022 OSE Immunotherapeutics Builds a Strong R&D Strategy Through Innovative First-in-Class Multi-Platform Programs
03/11/2022 OSE Immunotherapeutics Announces Award for OSE-127's Upcoming Oral Presentation in Acute Lymphoblastic Leukemia at the 2022 American Society of Hematology (ASH) Annual Meeting
03/11/2022 Servier and OSE Immunotherapeutics announce completion of patient enrollment in the Phase 2a clinical trial of OSE-127/S95011 in primary Sjögren’s syndrome
20/10/2022 OSE Immunotherapeutics Updates on Tedopi®, a Cancer Vaccine as Potential New Standard of Care in Non-Small Cell Lung Cancer After Failure to Immunotherapies
12/10/2022 OSE Immunotherapeutics Presents Update on BiCKI®-IL-7v and CLEC-1 Immuno-Oncology Programs at International Conferences
07/10/2022 OSE Immunotherapeutics Appoints Nicolas Poirier as Chief Executive Officer
22/09/2022 OSE Immunotherapeutics Announces Corporate Update and H1 2022 Results
08/09/2022 OSE Immunotherapeutics Announces Participation In Upcoming Investor Conferences
05/09/2022 OSE Immunotherapeutics to Present New Data on Tedopi® from Phase 3 Clinical Trial in Patients with Advanced Non-Small Cell Lung Cancer after Failure to Immune Checkpoint Inhibitors at ESMO Congress 2022
1 2 3 4 5 6 7 8 9 10 11 12 13